Boaz Hirshberg, MD

Articles by Boaz Hirshberg, MD

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

ByDavid M. Kern, MS,Stephanie DeVore, MSPH,Jennifer Kim, PharmD,Ozgur Tunceli, PhD,Bingcao Wu, MS,Boaz Hirshberg, MD

March 18th 2015

Targeting glucose control and managing cardiovascular (CV) risk factors may prevent future CV events, and have positive downstream impact by reducing costs to healthcare stakeholders.

Latest Updated Articles

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease
March 18th 2015

Boaz Hirshberg, MD

Articles by Boaz Hirshberg, MD

Mortality, Outcomes, and Healthcare Costs in T2DM Patients at Risk for Cardiovascular Disease

Latest Updated Articles

Trending on AJMC

Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home

Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS

Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship

New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease

CAR T Therapy Likely the Next Frontier for Treating Patients With MG: James F. Howard, MD